REVIVA PHARMA HLDGS INC (RVPH) Financials

RVPH

FY2025 annual

Revenue Not reported for FY2025

Net Income -$19.9M +33.6% YoY

EPS (Diluted) Not reported for FY2025

Operating Cash Flow -$24.6M +26.7% YoY

Market Cap $6.6M as of Oct 7, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 0.4x on $15.2M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 7, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 12, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RVPH SEC filings page.

This page shows REVIVA PHARMA HLDGS INC (RVPH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RVPH FY2025 2026-10-03

Reviva remains a development-stage business: 2025 losses narrowed as R&D fell, while financing still supplied the cash operations consumed.

The 2025 net loss narrowed to $19.9M from $29.9M in 2024, but operating cash flow remained more negative than earnings at -$24.6M. That gap indicates cash demands outside the reported loss persisted, although the available figures do not identify their exact source.

R&D fell to $11.7M in 2025 from $22.9M, closely tracking the improvement in operating loss. With no revenue reported, the visible driver is expense reduction, not sales growth or margin expansion.

The balance sheet became less liability-heavy: total liabilities fell to $7.3M from $14.7M, while debt-to-equity declined to 0.8x. Positive financing cash flow of $25.6M roughly offset operating cash flow of -$24.6M, showing that external funding, rather than internally generated cash, supported 2025 activity.

Financial Health Signals

Financial health score not available

REVIVA PHARMA HLDGS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

REVIVA PHARMA HLDGS INC passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

REVIVA PHARMA HLDGS INC reported a net loss of $19.9M while operations used $24.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

REVIVA PHARMA HLDGS INC reported an operating loss of $20.2M against $13K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

-$2.4M

YoY+59.6%

QoQ+23.4%

REVIVA PHARMA HLDGS INC reported -$2.4M in net income in Q2 2026. This represents an increase of 59.6% from the same quarter a year earlier. Against the prior quarter it is up 23.4%.

Revenue

Not reported for Q2 2026.

EBITDA

Not reported for Q2 2026.

EPS (Diluted)

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$19.9M

YoY+91.9%

QoQ-10.4%

5Y CAGR-11.1%

REVIVA PHARMA HLDGS INC held $19.9M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

13M

QoQ0.0%

5Y CAGR-0.4%

REVIVA PHARMA HLDGS INC had 13M shares outstanding in Q2 2026. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-16.1%

QoQ+2.2pp

REVIVA PHARMA HLDGS INC's ROE was -16.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. Against the prior quarter it is up 2.2 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$1.4M

YoY-62.6%

QoQ-2.8%

REVIVA PHARMA HLDGS INC invested $1.4M in research and development in Q2 2026. This represents a decrease of 62.6% from the same quarter a year earlier. Against the prior quarter it is down 2.8%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

RVPH Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RVPH quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1910-K
R&D Expenses	N/A	$11.7M-48.9%	$22.9M-27.1%	$31.4M+37.4%	$22.9M+371.4%	$4.9M+1543.8%	$295K	N/A	N/A
SG&A Expenses	N/A	$8.5M+7.6%	$7.9M-2.4%	$8.1M+50.9%	$5.4M+2.0%	$5.3M+145.5%	$2.1M	N/A	N/A
Operating Income	N/A	-$20.2M+34.4%	-$30.8M+22.0%	-$39.5M-39.9%	-$28.2M-179.4%	-$10.1M-315.0%	-$2.4M	N/A	-$153K
EBITDA	N/A	N/A	N/A	N/A	N/A	-$10.1M-315.1%	-$2.4M	N/A	N/A
Interest Expense	N/A	$13K-27.5%	$18K-45.2%	$34K	N/A	$0-100.0%	$1.5M	N/A	$729K
Income Tax	N/A	$19K-3.2%	$20K+15.1%	$17K-18.4%	$21K+246.1%	$6K+650.5%	$8000.0%	$800	N/A
Net Income	N/A	-$19.9M+33.6%	-$29.9M+23.8%	-$39.3M-38.9%	-$28.3M-231.6%	-$8.5M-125.2%	-$3.8M	N/A	$574K
EPS (Basic)	N/A	-$5.48+69.1%	-$17.73-974.5%	-$1.65-13.8%	-$1.45-150.0%	-$0.58	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$1.4M-62.6%	$1.4M-65.1%	N/A	$2.1M-68.9%	$3.7M-33.3%	$4.1M-28.9%	N/A	$6.9M-28.4%
SG&A Expenses	$1.2M-47.9%	$1.8M-24.2%	N/A	$1.9M+18.3%	$2.3M-7.7%	$2.4M+13.4%	N/A	$1.6M-19.5%
Operating Income	-$2.6M+56.9%	-$3.3M+50.0%	N/A	-$4.0M+52.4%	-$6.1M+25.3%	-$6.5M+17.5%	N/A	-$8.5M+26.8%
Interest Expense	$3K-38.8%	$7K-42.7%	N/A	$3K-49.4%	$5K-6.9%	$12K+233.2%	N/A	$5K-12.8%
Income Tax	$3K-66.9%	$3K-35.8%	N/A	$3K	$8K+7.7%	$5K-29.5%	N/A	$0-100.0%
Net Income	-$2.4M+59.6%	-$3.2M+50.3%	N/A	-$4.0M+52.1%	-$6.1M+23.0%	-$6.4M+13.5%	N/A	-$8.4M+26.3%
EPS (Basic)	-$0.19+92.1%	-$0.46+82.4%	-$5.19+69.4%	-$0.06+76.0%	-$2.40-823.1%	-$2.61-944.0%	-$16.98-5045.5%	-$0.25+47.9%

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, EPS (Diluted), Diluted Shares (Avg).

RVPH Balance Sheet

RVPH quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1910-K
Total Assets	$15.9M+2.7%	$15.5M-34.6%	$23.7M+25.2%	$18.9M-39.7%	$31.4M+258.4%	$8.8M+336910.7%	$3K	$65.6M
Current Assets	$15.1M+2.9%	$14.7M-38.0%	$23.7M	N/A	N/A	$44K	N/A	$404K
Cash & Equivalents	$14.4M+7.1%	$13.5M-42.3%	$23.4M+26.2%	$18.5M-37.6%	$29.7M+238.9%	$8.8M+4538999.5%	$193	$313K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$7.3M-50.5%	$14.7M-18.3%	$18.0M+70.8%	$10.5M+287.5%	$2.7M-17.6%	$3.3M-51.6%	$6.8M	$60.6M
Current Liabilities	$7.3M-50.2%	$14.6M-15.0%	$17.2M+72.4%	$10.0M+324.9%	$2.3M+75.9%	$1.3M+1231.4%	$100K	$23K
Non-Current Liabilities	$0-100.0%	$89K-89.0%	$807K+42.2%	$567K+52.2%	$373K-81.0%	$2.0M-70.8%	$6.7M	$60.6M
Total Equity	$8.6M+964.2%	$813K-85.8%	$5.7M-31.9%	$8.4M-70.7%	$28.7M+424.8%	$5.5M+180.2%	-$6.8M	$5.0M
Retained Earnings	-$184.1M-12.1%	-$164.3M-22.3%	-$134.4M-41.3%	-$95.1M-42.3%	-$66.8M-14.6%	-$58.3M-6.9%	-$54.5M	$574K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$21.1M+81.7%	$23.6M+232.9%	$15.9M+2.7%	$14.3M+87.8%	$11.6M+44.5%	$7.1M-47.6%	$15.5M-34.6%	$7.6M+41.6%
Current Assets	$21.1M+95.5%	$23.6M+276.5%	$15.1M+2.9%	$13.5M+98.4%	$10.8M+49.5%	$6.3M	$14.7M-38.0%	$6.8M
Cash & Equivalents	$19.9M+91.9%	$22.2M+319.5%	$14.4M+7.1%	$13.2M+137.2%	$10.4M+67.7%	$5.3M-55.8%	$13.5M-42.3%	$5.6M+11.8%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$5.9M-50.9%	$6.1M-47.0%	$7.3M-50.5%	$9.8M-44.5%	$12.1M-14.2%	$11.5M-22.3%	$14.7M-18.3%	$17.6M-3.2%
Current Liabilities	$5.9M-50.9%	$6.1M-46.8%	$7.3M-50.2%	$9.7M-44.5%	$12.1M-13.4%	$11.5M-20.6%	$14.6M-15.0%	$17.5M+1.2%
Non-Current Liabilities	$0-100.0%	$0-100.0%	$0-100.0%	$45K-42.9%	$17K-88.9%	$28K-92.1%	$89K-89.0%	$78K-91.1%
Total Equity	$15.2M+3412.1%	$17.4M+491.0%	$8.6M+964.2%	$4.5M+145.6%	-$459K+92.4%	-$4.5M-231.4%	$813K-85.8%	-$10.0M+22.1%
Retained Earnings	-$189.8M-7.4%	-$187.3M-9.7%	-$184.1M-12.1%	-$180.8M-14.4%	-$176.8M-18.1%	-$170.7M-20.4%	-$164.3M-22.3%	-$158.0M-26.4%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

RVPH Cash Flow Statement

RVPH quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1910-K
Operating Cash Flow	-$17.3M	-$24.6M+26.7%	-$33.5M-18.4%	-$28.3M-49.4%	-$19.0M-77.7%	-$10.7M-162.3%	-$4.1M	N/A	-$221K
Depreciation & Amortization	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$591-8.4%	$645	N/A
Stock-Based Compensation	N/A	$2.2M+36.6%	$1.6M-52.2%	$3.4M+1831.3%	$177K+65.6%	$107K	$0	$0	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$64.5M
Financing Cash Flow	$26.8M	$25.6M+8.1%	$23.7M-28.7%	$33.2M+325.7%	$7.8M-75.3%	$31.6M+146.3%	$12.8M	N/A	$65.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$2.1M+57.8%	-$3.8M+53.6%	-$5.8M+36.3%	-$5.6M-31.8%	-$5.0M+40.9%	-$8.2M+30.1%	-$9.1M-2.5%	-$4.2M+31.4%
Stock-Based Compensation	$215K-45.7%	$584K-36.4%	N/A	$458K+31.7%	$395K+10.1%	$919K+149.0%	N/A	$348K-0.7%
Financing Cash Flow	-$185K-101.8%	$11.6M+158787.8%	$7.1M-58.6%	$8.4M+132.2%	$10.1M+276.3%	$7K-97.8%	$17.0M-37.6%	$3.6M

Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

RVPH Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RVPH quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1910-K
Return on Equity	-229.7%+3452.3pp	-3682.0%-2995.5pp	-686.5%-349.9pp	-336.7%-307.0pp	-29.7%+39.5pp	-69.2%	N/A	11.5%
Return on Assets	-124.8%+68.2pp	-193.0%-27.3pp	-165.7%-16.3pp	-149.3%-122.2pp	-27.1%+16.0pp	-43.2%	N/A	0.9%
Current Ratio	2.08+1.1x	1.01-0.4x	1.38	N/A	N/A	0.03	N/A	17.53
Debt-to-Equity	0.84-17.2x	18.08+14.9x	3.14+1.9x	1.25+1.2x	0.09-0.5x	0.60	N/A	12.13

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-16.1%	-18.3%	N/A	-88.1%	N/A	N/A	N/A	N/A
Return on Assets	-11.6%+40.4pp	-13.6%+77.3pp	N/A	-28.0%+81.7pp	-52.0%+45.6pp	-90.9%-35.8pp	N/A	-109.7%+101.0pp
Current Ratio	3.56+2.7x	3.85+3.3x	2.08+1.1x	1.39+1.0x	0.90+0.4x	0.54	1.01-0.4x	0.39
Debt-to-Equity	0.39	0.35	0.84-17.2x	2.15	N/A	N/A	18.08+14.9x	N/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
REVIVA PHARMA HLDGS INC RVPH	FY2025	N/A	-$19.9M	N/A	$6.6M	—
Kezar Life Sciences, Inc. KZR	FY2025	$0	-$56.0M	N/A	$53.9M	—
Tenax Therapeutics, Inc. TENX	FY2025	$0	-$52.6M	N/A	$71.5M	—
Neuphoria Therapeutics Inc. NEUP	FY2026	$1.2M	-$13.5M	N/A	$18.5M	48/100
LakeShore Biopharma Co., Ltd LSB	FY2025	$85.7M	-$13.9M	-16.3%	$25.8M	48/100
OnKure Therapeutics, Inc. OKUR	FY2025	N/A	-$59.5M	N/A	$95.2M	—

Where REVIVA PHARMA HLDGS INC Ranks

Frequently Asked Questions

Is REVIVA PHARMA HLDGS INC profitable?

No, REVIVA PHARMA HLDGS INC (RVPH) reported a net income of -$19.9M in fiscal year 2025.

What is REVIVA PHARMA HLDGS INC's return on equity (ROE)?

REVIVA PHARMA HLDGS INC (RVPH) has a return on equity of -229.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is REVIVA PHARMA HLDGS INC's operating cash flow?

REVIVA PHARMA HLDGS INC (RVPH) recorded an outflow of $24.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are REVIVA PHARMA HLDGS INC's total assets?

REVIVA PHARMA HLDGS INC (RVPH) had $15.9M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does REVIVA PHARMA HLDGS INC spend on research and development?

REVIVA PHARMA HLDGS INC (RVPH) invested $11.7M in research and development during fiscal year 2025.

How many shares does REVIVA PHARMA HLDGS INC have outstanding?

REVIVA PHARMA HLDGS INC (RVPH) had 13M shares outstanding as of fiscal year 2025.

What is REVIVA PHARMA HLDGS INC's current ratio?

REVIVA PHARMA HLDGS INC (RVPH) had a current ratio of 2.08 as of fiscal year 2025, which is generally considered healthy.

What is REVIVA PHARMA HLDGS INC's debt-to-equity ratio?

REVIVA PHARMA HLDGS INC (RVPH) had a debt-to-equity ratio of 0.84 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is REVIVA PHARMA HLDGS INC's return on assets (ROA)?

REVIVA PHARMA HLDGS INC (RVPH) had a return on assets of -124.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is REVIVA PHARMA HLDGS INC's P/E ratio?

REVIVA PHARMA HLDGS INC (RVPH) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $6.6M as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is REVIVA PHARMA HLDGS INC's price-to-sales ratio?

REVIVA PHARMA HLDGS INC (RVPH) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $6.6M as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does REVIVA PHARMA HLDGS INC's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, REVIVA PHARMA HLDGS INC (RVPH) held $14.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $24.6M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is REVIVA PHARMA HLDGS INC's Piotroski F-Score?

REVIVA PHARMA HLDGS INC (RVPH) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are REVIVA PHARMA HLDGS INC's earnings high quality?

REVIVA PHARMA HLDGS INC (RVPH) reported a net loss of $19.9M while operations used $24.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can REVIVA PHARMA HLDGS INC cover its interest payments?

REVIVA PHARMA HLDGS INC (RVPH) reported an operating loss of $20.2M against $13K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.